About: Surface vimentin is critical for the cell entry of SARS-CoV

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Surface vimentin is critical for the cell entry of SARS-CoV Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Surface vimentin is critical for the cell entry of SARS-CoV
Creator	Chang, Ming-Fu Chen, I-Yin Chien, Ssu-Chia Lai, Chia-Tsen Tsay, Yeou-Guang Yu, Ting-Chun Chang, Shin
source	Medline; PMC
abstract	BACKGROUND: Severe acute respiratory syndrome coronavirus (SARS-CoV) caused a global panic due to its high morbidity and mortality during 2002 and 2003. Soon after the deadly disease outbreak, the angiotensin-converting enzyme 2 (ACE2) was identified as a functional cellular receptor in vitro and in vivo for SARS-CoV spike protein. However, ACE2 solely is not sufficient to allow host cells to become susceptible to SARS-CoV infection, and other host factors may be involved in SARS-CoV spike protein-ACE2 complex. RESULTS: A host intracellular filamentous cytoskeletal protein vimentin was identified by immunoprecipitation and LC-MS/MS analysis following chemical cross-linking on Vero E6 cells that were pre-incubated with the SARS-CoV spike protein. Moreover, flow cytometry data demonstrated an increase of the cell surface vimentin level by 16.5 % after SARS-CoV permissive Vero E6 cells were treated with SARS-CoV virus-like particles (VLPs). A direct interaction between SARS-CoV spike protein and host surface vimentin was further confirmed by far-Western blotting. In addition, antibody neutralization assay and shRNA knockdown experiments indicated a vital role of vimentin in cell binding and uptake of SARS-CoV VLPs and the viral spike protein. CONCLUSIONS: A direct interaction between vimentin and SARS-CoV spike protein during viral entry was observed. Vimentin is a putative anti-viral drug target for preventing/reducing the susceptibility to SARS-CoV infection.
has issue date	2016-01-22(xsd:dateTime)
bibo:doi	10.1186/s12929-016-0234-7
bibo:pmid	26801988
has license	cc-by
sha1sum (hex)	634b79269e0f00d35bcea1a2dc7643884b8c6b3a
schema:url	https://doi.org/10.1186/s12929-016-0234-7
resource representing a document's title	Surface vimentin is critical for the cell entry of SARS-CoV
has PubMed Central identifier	PMC4724099
has PubMed identifier	26801988
schema:publication	J Biomed Sci
resource representing a document's body	covid:634b79269e0f00d35bcea1a2dc7643884b8c6b3a#body_text
is schema:about of	named entity 'SARS-CoV' named entity 'angiotensin-converting enzyme 2' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS' named entity 'SOON AFTER' named entity 'DISEASE OUTBREAK' named entity 'MORBIDITY AND MORTALITY' named entity 'ITS' named entity 'FUNCTIONAL' named entity 'PANIC' named entity 'RECEPTOR' named entity 'BACKGROUND' named entity 'HIGH' named entity 'SPIKE PROTEIN' named entity 'ANGIOTENSIN-CONVERTING ENZYME 2' named entity 'CELLULAR' named entity 'DUE TO' named entity 'SARS-COV' named entity 'GLOBAL' named entity 'IDENTIFIED' named entity 'SURFACE' named entity 'CRITICAL' named entity 'ENTRY' named entity 'VIMENTIN' named entity 'IN VIVO' named entity 'CAUSED' named entity 'THE CELL' named entity 'SARS-COV' named entity 'IN VITRO' covid:arg/634b79269e0f00d35bcea1a2dc7643884b8c6b3a named entity 'deadly' named entity 'mortality' named entity 'protein' named entity 'SARS-CoV' named entity 'spike' named entity 'infection' named entity 'vimentin' named entity 'Asp' named entity 'Flow Cytometer' named entity 'SARS-CoV' named entity 'antibodies' named entity 'ACE2' named entity 'culture medium' named entity 'antibodies' named entity 'infection' named entity 'pathogen' named entity 'SARS-CoV' named entity 'cell type' named entity 'protein kinases' named entity 'Vero E6' named entity 'SARS-CoV' named entity 'SARS-CoV' named entity 'VLPs' named entity 'SARS-CoV' named entity 'ACE2' named entity 'positive control' named entity 'DC-SIGN' named entity 'ACE2' named entity 'vimentin' named entity 'cell surface' named entity 'ACE2' named entity 'drug development' named entity 'virus' named entity 'African swine fever virus' named entity 'vimentin' named entity 'SARS-CoV' named entity 'Confocal Microscopy' named entity 'vimentin' named entity 'SARS-CoV' named entity 'protein' named entity 'vimentin' named entity 'viral entry' named entity 'SARS-CoV' named entity 'vimentin' named entity 'vimentin' named entity 'ACE2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software